Precision BioSciences reports positive interim data from Phase 1/2a lymphoma, leukemia study

Precision BioSciences (NASDAQ:DTIL) reported positive interim results from its Phase 1/2a study evaluating PBCAR0191, an allogeneic chimeric antigen receptor (CAR-T) cell therapy, for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL). 

The interim report includes data from 27 patients with NHL and 11 patients with B-ALL who received multiple dose levels of PBCAR0191. Patients across NHL and B-ALL groups who received PBCAR0191 with enhanced lymphodepletion demonstrated an 83% objective response rate at day 28 or later.

At day 28 or later, 75% of NHL patients who received PBCAR0191 with enhanced lymphodepletion achieved a complete response; while 33% of NHL patients across the second and third PBCAR0191 dosing level with standard lymphodepletion, achieved a complete response.

“PBCAR0191, when combined with enhanced lymphodepletion resulted in a high objective response rate of 83% across enrolled NHL and B-ALL patients including those that previously received autologous CAR-T therapy or stem cell transplants,” Matt Kane, Precision BioSciences’ co-founder and CEO, said in a statement.

“We believe that this data set represents an important and meaningful step forward in the development of allogeneic CAR-T therapies and establishes Precision BioSciences as a leader in the field,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.